Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RILVE Project in advanced gastric cancer
2026-525620-23-00Phase 2Authorised
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of rilvegostomig and pembrolizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Immune biomarker modulation from baseline to post-window biopsy. Planned start Jul 2026; status: authorised.
02
Drugs
rilvegostomigpembrolizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2026-525620-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525620-23-00.